following a full submission:
tofacitinib (Xeljanz®) is accepted for use within NHSScotland.
Indication under review: for the treatment of adult patients with active ankylosing spondylitis (AS) who have responded inadequately to conventional therapy.
In a phase III and phase II study, tofacitinib compared with placebo, significantly improved symptoms of AS in adults with active disease inadequately controlled with nonsteroidal anti-inflammatory drugs.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.
Medicine details
- Medicine name:
- tofacitinib (Xeljenz)
- SMC ID:
- SMC2463
- Indication:
For treatment of adult patients with active ankylosing spondylitis (AS) who have responded inadequately to conventional therapy
- Pharmaceutical company
- Pfizer Ltd
- BNF chapter
- Musculoskeletal and joint diseases
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 12 September 2022